KIRKLAND, Wash.--(BUSINESS WIRE)--ProteoTech Inc. ("ProteoTech"), a privately held biotechnology company developing innovative treatments for amyloid diseases and misfolded protein disorders, announced today that Roger S. Flugel, Ph.D. has been appointed as Chief Executive Officer. Dr. Flugel has also been elected as a Director on the company’s Board of Directors. "ProteoTech is very pleased that Dr. Flugel has agreed to serve as CEO of our company. With his experience and proven leadership in building biotechnology companies and successfully developing therapeutic drugs, we know that our company is well positioned to achieve the full potential of its therapeutic technology platform," said William T. Frantz, Chairman of the Board of ProteoTech.
"I believe that ProteoTech is uniquely positioned to successfully develop innovative new treatments for serious rare diseases, as well as more prevalent conditions, due to its unique small molecule drug technology platform, world-class team, and extensive intellectual property. I am grateful to the Board of Directors for this opportunity, and I am excited to lead the talented and dedicated team at ProteoTech towards reaching our company’s maximum potential. I am passionate about ProteoTech’s prospects, and I look forward to working with the entire team in order to benefit patients, physicians, and all stakeholders," said Dr. Flugel.
Prior to joining ProteoTech, Dr. Roger Flugel was the CEO of TheraVida, Inc. (Mountain View, CA) from 2007 to 2013, and before that, was a Principal with Sanderling Ventures, where he served in a variety of roles as Director, Chairman, CEO, or board observer at several of their portfolio companies. While at Sanderling, he assisted in the completion of strategic corporate transactions for Kadmus Pharmaceuticals (acquired by Schering-Plough, now Merck) and Aderis Pharmaceuticals (acquired by Schwarz Pharma, now UCB). Prior to Sanderling Ventures, Dr. Flugel served as the Director of Venture Analysis at HealthCare Ventures. Dr. Flugel is now responsible for representing ProteoTech in all business transactions and partnerships. Dr. Flugel received his Ph.D. in Biophysics from Harvard University, conducting his research in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School.
About ProteoTech, Inc.
ProteoTech is a privately-held, drug development company that utilizes its amyloid expertise to discover and develop new drugs for treating misfolded protein disorders and amyloid diseases. ProteoTech’s lead small molecule drug, Systebryl™ (PTI-110), will soon be entering a Phase 1/2 proof-of-concept clinical trial in patients with AL (immunoglobulin light chain) amyloidosis (a recognized rare or "orphan" disease). Other products in the ProteoTech pipeline include a small molecule drug that is designed to inhibit and stimulate the reduction of insoluble alpha-synuclein aggregate accumulation (involved in Multiple System Atrophy and Parkinson’s disease), small molecule drugs intended to inhibit and reduce tau protein and/or beta-amyloid protein aggregates (involved in Progressive Supranuclear Palsy and Alzheimer’s disease), and small molecule drugs intended to inhibit and reduce beta-2 microglobulin protein aggregates (involved in dialysis-related amyloidosis). For further information, please visit www.proteotech.com, email email@example.com, or telephone +1-425-823-0400.